GlassScriptPhysician profile
Jeffrey Obiora
NPI 1023547460
$3,344.71
in general payments reported to CMS, 2019-2025
33 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $651 · 2023: $1,069 · 2024: $1,008 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,477 · Education: $69.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,477.32 |
| Education | $69.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $566.11 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $338.52 | 2023-2025 | |
| Novo Nordisk INC | $297.18 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $244.95 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $209.92 | 2022-2025 | |
| Astellas Pharma US INC | $187.78 | 2023-2025 | Veozah |
| Pfizer INC. | $128.01 | 2021-2025 | |
| Dexcom, INC. | $121.66 | 2022-2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $113.58 | 2022-2024 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $107.37 | 2022-2024 | |
| Amgen INC. | $95.42 | 2023-2025 | Repatha, Otezla, Evenity |
| Inspire Medical Systems, INC. | $93.59 | 2024-2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $85.53 | 2021-2023 | Rexulti |
| Edwards Lifesciences Corporation | $83.22 | 2022-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Exact Sciences Corporation | $71.81 | 2023-2025 | Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $66.25 | 2025 | |
| Merck Sharp & Dohme LLC | $62.20 | 2022-2024 | Gardasil, Gardasil 9, Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $49.71 | 2022 | |
| Sanofi Pasteur INC. | $49.29 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.55 | 2021-2022 | |
| Abbott Laboratories | $38.84 | 2022-2025 | Freestyle Libre 3 |
| Linus Health, INC. | $37.46 | 2022-2023 | |
| Medtronic, INC. | $33.77 | 2024 | Intellis Adaptivestim, Interstim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.31 | 2022-2024 | |
| Boston Scientific Corporation | $30.38 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $27.78 | 2025 | Neffy |
| Gilead Sciences, INC. | $23.94 | 2023 | |
| Biogen, INC. | $20.49 | 2024 | Leqembi |
| Biotronik Nro, INC. | $19.42 | 2024 | Prospera |
| Philips North America LLC | $18.18 | 2024 | (Ck7) Extended Holter |
| Neos Therapeutics, LP | $16.32 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.10 | 2023 | Quviviq |
| Amarin Pharma, INC. | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Obiora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.